Skip to main content
. Author manuscript; available in PMC: 2016 Dec 28.
Published in final edited form as: J Control Release. 2015 Sep 25;220(0 0):715–726. doi: 10.1016/j.jconrel.2015.09.040

Figure 3.

Figure 3

a) Spatial heterogeneity in HER2 expression between three different areas of an invasive ductal carcinoma biopsy sample. HER2 amplification was confirmed using immunohistochemistry (IHC) and silver in situ hybridization (SISH). H&E, ×200; IHC, ×200; SISH, ×400. Reprinted with permission from Lee et al. [57]. b) Progression free survival (top) and overall survival (bottom) of high-grade serous ovarian cancer patients treated with platinum-based chemotherapy and surgery, stratified by degree of clonal expansion (CE). CE reflects the accumulation of mutations that promote cell expansion into varying subclonal populations from the original cell. Higher CE is correlated with divergent subclonal populations and thus greater tumor heterogeneity. Reprinted with permission from Schwarz et al. [58].